Held by 3 specialist biotech funds
High Convergence# Signal Note: BVF Partners Initiates TENX Position **Summary:** Biotech value investor BVF Partners initiated a $4.1M stake in Tenax Therapeutics, likely betting on near-term catalysts in the company's pulmonary hypertension pipeline.
AI analyst context — unlock full analysis
# Signal Note: Perceptive Advisors initiates TENX position Edelman's $5.4M entry into TENX likely reflects conviction in LSBK-0414, the company's Phase 2b candidate for pulmonary arterial hypertension (PAH), which addresses an underserved patient population with significant unmet need in combination therapy. The timing suggests positioning ahead of near-term clinical readouts or potential partnership catalysts, given Perceptive's historical focus on clinical-stage value creation and Edelman's track record of identifying inflection points before market recognition.
+ 1more — see how much conviction went in
See the Full Story